VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vir Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.21+0.25 (+2.51%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.43 (+76.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Vir Biotechnology, Inc. grew revenue 1495.9% to $303.23M over the twelve months to Jun 30, 2026. Free cash flow was -$203.59M.
Revenue
$303.23M
+1495.9% vs. a year earlier
Operating income
-$280.19M
TTM Q2 2026
Free cash flow
-$203.59M
TTM Q2 2026
EPS, diluted
-$1.86
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.72B
- P/E ratio
- –
- Price to sales
- 5.69
- Price to book
- 1.75
- Dividend yield
- –
- Free cash flow yield
- -11.81%
Fundamentals
- Revenue
- $303.23M
- Net income
- -$251.68M
- EPS, diluted
- -$1.86
- Free cash flow
- -$203.59M
- Book value per share
- $5.82
- Diluted shares
- 169M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$303.23M+1495.9% YoY
Gross profit
–
Operating income
-$280.19M
Net income
-$251.68M
EPS, diluted
-$1.86
Free cash flow
-$203.59M
Reported periodTrailing twelve months